Company profile
UK company NI656568, incorporated on 23 October 2018.
Sonotarg - A New Approach
SonoTarg has developed a new approach to cancer therapy that minimises the adverse effects associated with conventional chemotherapy.
Company number NI656568
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
RP01AP01 | Transaction MzUzNzIzMjYwN2FkaXF6a2N4
Published 07 Aug 2026 13:03
MA | Transaction MzUzNzMyMTUzNGFkaXF6a2N4 | Paper/PDF filed
Published 11 Aug 2026 12:06
RESOLUTIONS | Transaction WUY3V1FKOVVhZGlxemtjeA | Paper/PDF filed
Published 07 Aug 2026 23:08
AP01 | Transaction MzUzNzIzMDI2MGFkaXF6a2N4 | Paper/PDF filed
Published 07 Aug 2026 23:01
SH01 | Transaction MzUzNzIzNjcwMGFkaXF6a2N4
Published 05 Aug 2026 16:53
AP01 | Transaction MzUzNzIzMTg0MWFkaXF6a2N4
Published 05 Aug 2026 15:47
Company registered at Companies House
SonoTarg develops drug delivery technology that aims to specifically treat tumours.
The company's aim is to commercial the technology developed jointly by Ulster and Oxford Universities for the treatment of pancreatic cancer using microbubble mediated drug delivery.
The company has only just been formed
1 Jun 2025 to 31 May 2026
SonoTarg, a spinout company from Ulster University and based at Coleraine, is exploiting its proprietary ultrasound-responsive microbubble platform for the treatment of pancreatic cancer. The ultrasound-responsive microbubble platform enables the delivery of low dose chemotherapy, in combination with sonodynamic therapy (SDT) to provide highly effective t...
